Literature DB >> 24550228

XMEN disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus.

Feng-Yen Li1, Benjamin Chaigne-Delalande, Helen Su, Gulbu Uzel, Helen Matthews, Michael J Lenardo.   

Abstract

Epstein-Barr virus (EBV) is an oncogenic gammaherpesvirus that infects and persists in 95% of adults worldwide and has the potential to cause fatal disease, especially lymphoma, in immunocompromised hosts. Primary immunodeficiencies (PIDs) that predispose to EBV-associated malignancies have provided novel insights into the molecular mechanisms of immune defense against EBV. We have recently characterized a novel PID now named "X-linked immunodeficiency with magnesium defect, EBV infection, and neoplasia" (XMEN) disease characterized by loss-of-function mutations in the gene encoding magnesium transporter 1 (MAGT1), chronic high-level EBV with increased EBV-infected B cells, and heightened susceptibility to EBV-associated lymphomas. The genetic etiology of XMEN disease has revealed an unexpected quantitative role for intracellular free magnesium in immune functions and has led to novel diagnostic and therapeutic strategies. Here, we review the clinical presentation, genetic mutation spectrum, molecular mechanisms of pathogenesis, and diagnostic and therapeutic considerations for this previously unrecognized disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24550228      PMCID: PMC3975255          DOI: 10.1182/blood-2013-11-538686

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

Review 1.  Epstein-Barr virus infection.

Authors:  J I Cohen
Journal:  N Engl J Med       Date:  2000-08-17       Impact factor: 91.245

2.  Patients with X-linked lymphoproliferative disease have a defect in 2B4 receptor-mediated NK cell cytotoxicity.

Authors:  H Nakajima; M Cella; A Bouchon; H L Grierson; J Lewis; C S Duckett; J I Cohen; M Colonna
Journal:  Eur J Immunol       Date:  2000-11       Impact factor: 5.532

Review 3.  Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.

Authors:  Nima Rezaei; Mona Hedayat; Asghar Aghamohammadi; Kim E Nichols
Journal:  J Allergy Clin Immunol       Date:  2011-04-22       Impact factor: 10.793

4.  Pharmacodynamics of rituximab in kidney allotransplantation.

Authors:  H Genberg; A Hansson; A Wernerson; L Wennberg; G Tydén
Journal:  Am J Transplant       Date:  2006-08-21       Impact factor: 8.086

5.  Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation.

Authors:  Veronika Groh; Jennifer Wu; Cassian Yee; Thomas Spies
Journal:  Nature       Date:  2002-10-17       Impact factor: 49.962

6.  Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors.

Authors:  Yenan T Bryceson; Hans-Gustaf Ljunggren; Eric O Long
Journal:  Blood       Date:  2009-07-23       Impact factor: 22.113

7.  Mammalian MagT1 and TUSC3 are required for cellular magnesium uptake and vertebrate embryonic development.

Authors:  Hao Zhou; David E Clapham
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-26       Impact factor: 11.205

8.  SAP mediates specific cytotoxic T-cell functions in X-linked lymphoproliferative disease.

Authors:  Reza Sharifi; Joanna C Sinclair; Kimberly C Gilmour; Peter D Arkwright; Christine Kinnon; Adrian J Thrasher; H Bobby Gaspar
Journal:  Blood       Date:  2004-01-15       Impact factor: 22.113

Review 9.  Primary immunodeficiencies predisposed to Epstein-Barr virus-driven haematological diseases.

Authors:  Nima Parvaneh; Alexandra H Filipovich; Arndt Borkhardt
Journal:  Br J Haematol       Date:  2013-06-11       Impact factor: 6.998

10.  The switch from latent to productive infection in epstein-barr virus-infected B cells is associated with sensitization to NK cell killing.

Authors:  Isabel Y Pappworth; Eddie C Wang; Martin Rowe
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

View more
  61 in total

Review 1.  Genomics of Immune Diseases and New Therapies.

Authors:  Michael Lenardo; Bernice Lo; Carrie L Lucas
Journal:  Annu Rev Immunol       Date:  2015-12-23       Impact factor: 28.527

Review 2.  X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection, and neoplasia disease: a combined immune deficiency with magnesium defect.

Authors:  Juan Ravell; Benjamin Chaigne-Delalande; Michael Lenardo
Journal:  Curr Opin Pediatr       Date:  2014-12       Impact factor: 2.856

3.  Successful Bone Marrow Transplantation for XMEN: Hemorrhagic Risk Uncovered.

Authors:  Dimana Dimitrova; Jeremy J Rose; Gulbu Uzel; Jeffrey I Cohen; Koneti V Rao; Jacob H Bleesing; Christopher G Kanakry; Jennifer A Kanakry
Journal:  J Clin Immunol       Date:  2018-11-23       Impact factor: 8.317

Review 4.  Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant.

Authors:  Rayne H Rouce; Chrystal U Louis; Helen E Heslop
Journal:  Curr Opin Hematol       Date:  2014-11       Impact factor: 3.284

5.  Clinical utility gene card for: X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection, and neoplasia (XMEN).

Authors:  Feng-Yen Li; Benjamin Chaigne-Delalande; V Koneti Rao; Yu Zhang; Helen Matthews; Taco Tw Kuijpers; Helen Su; Gulbu Uzel; Michael J Lenardo
Journal:  Eur J Hum Genet       Date:  2014-09-10       Impact factor: 4.246

Review 6.  Divalent cation signaling in immune cells.

Authors:  Benjamin Chaigne-Delalande; Michael J Lenardo
Journal:  Trends Immunol       Date:  2014-06-02       Impact factor: 16.687

7.  Heme exporter FLVCR is required for T cell development and peripheral survival.

Authors:  Mary Philip; Scott A Funkhouser; Edison Y Chiu; Susan R Phelps; Jeffrey J Delrow; James Cox; Pamela J Fink; Janis L Abkowitz
Journal:  J Immunol       Date:  2015-01-12       Impact factor: 5.422

Review 8.  Human inborn errors of immunity to herpes viruses.

Authors:  Emmanuelle Jouanguy; Vivien Béziat; Trine H Mogensen; Jean-Laurent Casanova; Stuart G Tangye; Shen-Ying Zhang
Journal:  Curr Opin Immunol       Date:  2020-01-31       Impact factor: 7.486

Review 9.  An Update on the Use of Immunomodulators in Primary Immunodeficiencies.

Authors:  Pandiarajan Vignesh; Amit Rawat; Surjit Singh
Journal:  Clin Rev Allergy Immunol       Date:  2017-04       Impact factor: 8.667

10.  The Many Faces of XMEN Disease, Report of Two Patients with Novel Mutations.

Authors:  Rodrigo Hoyos-Bachiloglu; Sara Concha; Pablo Sepúlveda; Roberto Campos; Guillermo Perez-Mateluna; Alejandra King; Pamela Zuñiga
Journal:  J Clin Immunol       Date:  2020-01-28       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.